The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance.    ,

 Bacillus amyloliquefaciens strain ISB06,Not applicable,No relevant impurities,1 January 2018,31 December 2027,3,  The authorisations of biocidal products are subject to the following conditions:      The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.      In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to professional users.    ,